LLY vs MRNA
By Alex · Tickerpine
Eli Lilly and Company vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | MRNA |
|---|---|---|
| Price | $1,184.78 | $197.28 |
| Market cap | $1.06T | $78.76B |
| P/E ratio | 39.7 | — |
| ROE | 102.29% | -39.00% |
| Profit margin | 33.53% | -141.43% |
| Revenue growth | 47.70% | 2.10% |
| Dividend yield | 0.58% | — |
| Beta | 0.50 | 1.11 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs MRNA in plain English
- LLY is the bigger company — about 13.4× the market cap of MRNA.
- LLY earns a higher return on equity (102% vs -39%).
- LLY is growing revenue faster (48% vs 2%).
- LLY pays a dividend (0.58%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.